Advanced bowel cancer cells have very few ‘molecular flags’ on their surface, helping to explain why they may be hard for the immune system to detect, a new study has shown.

Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.

A new test can genetically ‘barcode’ bowel cancer and separate it into five different diseases that could each receive tailored treatment, a new study reports.